Week In Review: Hepalink Pharma Buys US-Based CMO Cytovance
Shenzhen Hepalink Pharma will acquire Cytovance, a US biologics CMO, for $205 million; Shanghai Pharma will launch a $470 million China VC fund for China healthcare startups with partners; DynoSense, a San Jose medical device company, closed a $9.4 million Series A from China-US investors; Jiangxi Boya Bio-Pharma will acquire stakes in two China pharmas; Harbin Gloria Pharma plans to buy a 70% interest in Sheyang Zhenyang Hospital for $27.5 million; Cellular Research, a Silicon Valley genetics company supported by China's Decheng Capital, was acquired by BD Life Sciences; Shanghai Kehua Bio-Engineering signed an MOU to acquire Technogenetics of Italy in a diagnostics tie-up; ECM Medical, a US-China medical device company, acquired China rights to a novel spinal fusion device from Vertebral of Minnesota; Lee's Pharm acquired China rights to two single-dose infusion products from San Francisco-based BioQuiddity; Eddingpharm in-licensed greater China rights to a second CV drug from Canada's Cardiome; and the CFDA is developing a pilot plan to approve INDs for oncology drugs in 60 days.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.